Dasatinib Improves Outcomes in Patients With Chronic Myeloid Leukemia and High BMI

According to a subgroup analysis of a phase 3 study, dasatinib produces significantly faster and more durable responses compared with imatinib in patients with chronic phase chronic myeloid leukemia (CML) and a high body mass index (BMI). Previous studies have reported that patients with a high BMI, defined as over 25 kg/m 2 , are at an increased risk of not only developing CML but also of experiencing poorer outcomes when treated with first-line tyrosine kinase inhibitors (TKIs) such as imatini...
Continue reading

Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes , a gram-positive bacterium to which individuals with weakened immune systems are susceptible. Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an importan...
Continue reading

Transplant-Ineligible Myeloma: Adding Daratumumab to VMP Increases Survival

Adding daratumumab to bortezomib/melphalan/prednisone (VMP) increases overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), according to results of the phase 3 ALCYONE trial to be presented in December at the American Society of Hematology (ASH) Annual Meeting and Exposition. Patients who are ineligible for autologous stem cell transplantation comprise approximately half of NDMM patients, and the combination of bortezomib, a proteasome inhibitor, with m...
Continue reading

Moxetumomab Pasudotox-Tdfk Improves Outcomes in Hairy Cell Leukemia

According to long-term follow-up results of a phase 3 study, moxetumomab pasudotox-tdfk (Lumoxiti®, AstraZeneca) significantly improves responses in patients with relapsed/refractory hairy cell leukemia (HCL) who have received two or more prior therapies. Comprising 2% of all leukemias, HCL is a rare malignancy with limited treatment options. In September 2018, the FDA approved moxetumomab pasudotox-tdfk, a first-in-class recombinant CD22-directed cytotoxin, for the treatment of patients with re...
Continue reading

Zanubrutinib Approved for Mantle Cell Lymphoma

The FDA has approved zanubrutinib (Brukinsa®, BeiGene) for patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one previous therapy. The approval was based on two clinical trials. BGB-3111-206, a single-arm phase 2 trial, enrolled 86 patients with MCL whose disease progressed following at least one prior therapy. Patients received 160 mg of zanubrutinib orally twice daily until unacceptable toxicity or disease progression. The study's primary end point was ove...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.